Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 11 (November)

1. Photodynamic therapy for symptomatic circumscribed macular choroidal hemangioma in Chinese patients.
   Am J Ophthalmol, 150(5): 710-715.e1. [Abstract] [Full-text]
2. Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique.
   Am J Trop Med Hyg, 83(5): 1128-32. [Abstract] [Full-text]
3. Management of recurrent intussusception: nonoperative or operative reduction?
   J Pediatr Surg, 45(11): 2175-80. [Abstract] [Full-text]
4. Photodynamic therapy for symptomatic circumscribed macular choroidal hemangioma in Chinese patients.
   Am J Ophthalmol, 150(5): 710-715.e1. [Abstract] [Full-text]
5. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients?
   South Med J, 103(11): 1103-10. [Abstract] [Full-text]
6. A before-and-after study of fracture risk reporting and osteoporosis treatment initiation.
   Ann Intern Med, 153(9): 580-6. [Abstract] [Full-text]
7. Lumbar disc rehydration postimplantation of a posterior dynamic stabilization system.
   J Neurosurg Spine, 13(5): 576-80. [Abstract] [Full-text]
8. Effectiveness of an epidural blood patch for patients with intracranial hypotension syndrome and persistent spinal epidural fluid collection after treatment.
   J Neurosurg, 113(5): 940-6. [Abstract] [Full-text]
9. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes.
   J Acquir Immune Defic Syndr, 55: S5-9. [Abstract] [Full-text]
10. Dehydration followed by sham rehydration contributes to reduced neuronal activation in vasopressinergic supraoptic neurons after water deprivation.
    Am J Physiol Regul Integr Comp Physiol, 299(5): R1232-40. [Abstract] [Full-text]
11. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes.
    J Acquir Immune Defic Syndr, 55: S5-9. [Abstract] [Full-text]
12. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes.
    J Acquir Immune Defic Syndr, 55: S5-9. [Abstract] [Full-text]
13. Safety of recombinant activated factor VII in randomized clinical trials.
    N Engl J Med, 363(19): 1791-800. [Abstract] [Full-text]
14. Safety of recombinant activated factor VII in randomized clinical trials.
    N Engl J Med, 363(19): 1791-800. [Abstract] [Full-text]
15. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study.
    Am J Epidemiol, 172(10): 1181-9. [Abstract] [Full-text]
16. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Lancet Oncol, 11(11): 1036-47. [Abstract] [Full-text]
17. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
    Lancet Oncol, 11(11): 1066-73. [Abstract] [Full-text]
18. Liquid sclerotherapy for posttraumatic arteriovenous fistula of the radialis indicis artery.
    J Vasc Surg, 52(5): 1343-5. [Abstract] [Full-text]
19. Use of an automated circuit for isolated limb infusion for malignancy.
    Eur J Surg Oncol, 36(12): 1215-9. [Abstract] [Full-text]
20. Surgical treatment for peritoneal carcinomatosis from gastric cancer.
    Eur J Surg Oncol, 36(12): 1131-8. [Abstract] [Full-text]
21. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
    Gynecol Oncol, 119(3): 491-5. [Abstract] [Full-text]
22. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
    Eur J Surg Oncol, 36(12): 1156-61. [Abstract] [Full-text]
23. Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
    Eur J Surg Oncol, 36(12): 1187-94. [Abstract] [Full-text]
24. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.
    Gynecol Oncol, 119(3): 538-42. [Abstract] [Full-text]
25. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model.
    Gynecol Oncol, 119(3): 594-600. [Abstract] [Full-text]
26. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 119(3): 531-7. [Abstract] [Full-text]
27. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Gynecol Oncol, 119(3): 549-56. [Abstract] [Full-text]
28. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
    Gynecol Oncol, 119(3): 451-6. [Abstract] [Full-text]
29. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Gynecol Oncol, 119(3): 557-63. [Abstract] [Full-text]
30. Preemptive multimodal pain regimen reduces opioid analgesia for patients undergoing robotic-assisted laparoscopic radical prostatectomy.
    Urology, 76(5): 1122-4. [Abstract] [Full-text]
31. Use of an automated circuit for isolated limb infusion for malignancy.
    Eur J Surg Oncol, 36(12): 1215-9. [Abstract] [Full-text]
32. Surgical treatment for peritoneal carcinomatosis from gastric cancer.
    Eur J Surg Oncol, 36(12): 1131-8. [Abstract] [Full-text]
33. Cost-effectiveness of traditional and endovenous treatments for varicose veins.
    Br J Surg, 97(12): 1815-23; discussion 1823-4. [Abstract] [Full-text]
34. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
    Gynecol Oncol, 119(3): 491-5. [Abstract] [Full-text]
35. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
    Eur J Surg Oncol, 36(12): 1156-61. [Abstract] [Full-text]
36. Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
    Eur J Surg Oncol, 36(12): 1187-94. [Abstract] [Full-text]
37. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.
    Gynecol Oncol, 119(3): 538-42. [Abstract] [Full-text]
38. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model.
    Gynecol Oncol, 119(3): 594-600. [Abstract] [Full-text]
39. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 119(3): 531-7. [Abstract] [Full-text]
40. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Gynecol Oncol, 119(3): 549-56. [Abstract] [Full-text]
41. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
    Gynecol Oncol, 119(3): 451-6. [Abstract] [Full-text]
42. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Gynecol Oncol, 119(3): 557-63. [Abstract] [Full-text]
43. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
    Leuk Res, 34(12): 1622-6. [Abstract] [Full-text]
44. Developing and testing a patient information booklet for thrombolysis used in acute stroke.
    Int J Pharm Pract, 18(6): 362-9. [Abstract] [Full-text]
45. Use of an automated circuit for isolated limb infusion for malignancy.
    Eur J Surg Oncol, 36(12): 1215-9. [Abstract] [Full-text]
46. Surgical treatment for peritoneal carcinomatosis from gastric cancer.
    Eur J Surg Oncol, 36(12): 1131-8. [Abstract] [Full-text]
47. Cost-effectiveness of traditional and endovenous treatments for varicose veins.
    Br J Surg, 97(12): 1815-23; discussion 1823-4. [Abstract] [Full-text]
48. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
    Gynecol Oncol, 119(3): 491-5. [Abstract] [Full-text]
49. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
    Eur J Surg Oncol, 36(12): 1156-61. [Abstract] [Full-text]
50. Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
    Eur J Surg Oncol, 36(12): 1187-94. [Abstract] [Full-text]
51. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.
    Gynecol Oncol, 119(3): 538-42. [Abstract] [Full-text]
52. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model.
    Gynecol Oncol, 119(3): 594-600. [Abstract] [Full-text]
53. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 119(3): 531-7. [Abstract] [Full-text]
54. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Gynecol Oncol, 119(3): 549-56. [Abstract] [Full-text]
55. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
    Gynecol Oncol, 119(3): 451-6. [Abstract] [Full-text]
56. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Gynecol Oncol, 119(3): 557-63. [Abstract] [Full-text]
57. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
    Leuk Res, 34(12): 1622-6. [Abstract] [Full-text]
58. A prospective trial on the use of antibiotics in hand surgery.
    Plast Reconstr Surg, 126(5): 1617-23. [Abstract] [Full-text]
59. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Cochrane Database Syst Rev, 11: CD007461. [Abstract] [Full-text]
60. Antibiotic prophylaxis for third- and fourth-degree perineal tear during vaginal birth.
    Cochrane Database Syst Rev, 11: CD005125. [Abstract] [Full-text]
61. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.
    Cochrane Database Syst Rev, 11: CD003368. [Abstract] [Full-text]
62. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    Eur J Haematol, 85(6): 484-91. [Abstract] [Full-text]
63. Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003.
    Br J Haematol, 151(5): 447-59. [Abstract] [Full-text]
64. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    Eur J Haematol, 85(6): 484-91. [Abstract] [Full-text]
65. Targeted therapies for thymic malignancies.
    Thorac Surg Clin, 21(1): 115-23, viii. [Abstract] [Full-text]
66. Chemotherapy for thymic tumors: induction, consolidation, palliation.
    Thorac Surg Clin, 21(1): 107-14, viii. [Abstract] [Full-text]
67. Targeted therapies for thymic malignancies.
    Thorac Surg Clin, 21(1): 115-23, viii. [Abstract] [Full-text]
68. Chemotherapy for thymic tumors: induction, consolidation, palliation.
    Thorac Surg Clin, 21(1): 107-14, viii. [Abstract] [Full-text]
69. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials.
    Cancer Treat Rev, 36(8): 621-8. [Abstract] [Full-text]
70. Toward a molecular classification of cancer.
    Toxicology, 278(2): 195-8. [Abstract] [Full-text]
71. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.
    Cancer Cell, 18(5): 423-35. [Abstract] [Full-text]
72. Chemosensitization of human leukemia K562 cells to taxol by a Vanadium-salen complex.
    Exp Mol Pathol, 89(3): 334-42. [Abstract] [Full-text]
73. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials.
    Cancer Treat Rev, 36(8): 621-8. [Abstract] [Full-text]
74. Toward a molecular classification of cancer.
    Toxicology, 278(2): 195-8. [Abstract] [Full-text]
75. Chemosensitization of human leukemia K562 cells to taxol by a Vanadium-salen complex.
    Exp Mol Pathol, 89(3): 334-42. [Abstract] [Full-text]
76. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials.
    Cancer Treat Rev, 36(8): 621-8. [Abstract] [Full-text]
77. Toward a molecular classification of cancer.
    Toxicology, 278(2): 195-8. [Abstract] [Full-text]
78. The epidemiology of prescriptions abandoned at the pharmacy.
    Ann Intern Med, 153(10): 633-40. [Abstract] [Full-text]
79. Prevention of breast cancer (Part II): risk reduction strategies.
    Cancer Invest, 28(10): 1070-7. [Abstract] [Full-text]
80. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
    Cancer Invest, 28(10): 1048-53. [Abstract] [Full-text]
81. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines.
    Cancer Invest, 28(10): 1038-47. [Abstract] [Full-text]
82. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Cancer Invest, 28(10): 1078-83. [Abstract] [Full-text]
83. The epidemiology of prescriptions abandoned at the pharmacy.
    Ann Intern Med, 153(10): 633-40. [Abstract] [Full-text]
84. Opportunistic disorders of the gastrointestinal tract in the age of highly active antiretroviral therapy.
    Hum Pathol, 41(12): 1777-87. [Abstract] [Full-text]
85. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Cancer Sci, 101(12): 2591-5. [Abstract] [Full-text]
86. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
    Cancer Sci, 101(12): 2579-85. [Abstract] [Full-text]
87. Prevention of breast cancer (Part II): risk reduction strategies.
    Cancer Invest, 28(10): 1070-7. [Abstract] [Full-text]
88. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
    Cancer Invest, 28(10): 1048-53. [Abstract] [Full-text]
89. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines.
    Cancer Invest, 28(10): 1038-47. [Abstract] [Full-text]
90. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Cancer Invest, 28(10): 1078-83. [Abstract] [Full-text]
91. Opportunistic disorders of the gastrointestinal tract in the age of highly active antiretroviral therapy.
    Hum Pathol, 41(12): 1777-87. [Abstract] [Full-text]
92. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Cancer Sci, 101(12): 2591-5. [Abstract] [Full-text]
93. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
    Cancer Sci, 101(12): 2579-85. [Abstract] [Full-text]
94. Prevention of breast cancer (Part II): risk reduction strategies.
    Cancer Invest, 28(10): 1070-7. [Abstract] [Full-text]
95. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
    Cancer Invest, 28(10): 1048-53. [Abstract] [Full-text]
96. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    BJU Int, 106(11): 1677-80. [Abstract] [Full-text]
97. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines.
    Cancer Invest, 28(10): 1038-47. [Abstract] [Full-text]
98. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Cancer Invest, 28(10): 1078-83. [Abstract] [Full-text]
99. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    JAMA, 304(19): 2154-60. [Abstract] [Full-text]
100. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study.
     BMC Infect Dis, 10: 318. [Abstract] [Full-text]
101. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
     JAMA, 304(19): 2154-60. [Abstract] [Full-text]
102. Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation.
     Proc Natl Acad Sci U S A, 107(46): 19679-84. [Abstract] [Full-text]
103. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis.
     Proc Natl Acad Sci U S A, 107(46): 20027-32. [Abstract] [Full-text]
104. Endothelial estrogen receptor {alpha} plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion.
     Arterioscler Thromb Vasc Biol, 30(12): 2562-7. [Abstract] [Full-text]
105. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
     Radiology, 257(3): 643-52. [Abstract] [Full-text]
106. Endothelial estrogen receptor {alpha} plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion.
     Arterioscler Thromb Vasc Biol, 30(12): 2562-7. [Abstract] [Full-text]
107. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.
     Lancet Neurol, 9(12): 1182-99. [Abstract] [Full-text]
108. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
     J Clin Oncol, 28(33): 4945-52. [Abstract] [Full-text]
109. Automated drug dispensing system reduces medication errors in an intensive care setting.
     Crit Care Med, 38(12): 2275-81. [Abstract] [Full-text]
110. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.
     Lancet Neurol, 9(12): 1182-99. [Abstract] [Full-text]
111. Automated drug dispensing system reduces medication errors in an intensive care setting.
     Crit Care Med, 38(12): 2275-81. [Abstract] [Full-text]
112. Thickened fluids for people with dementia in residential aged care facilities.
     Int J Evid Based Healthc, 8(4): 252-5. [Abstract] [Full-text]
113. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
     Br J Cancer, 103(11): 1637-43. [Abstract] [Full-text]
114. Differentiating dental pulp cells via RGD-dendrimer conjugates.
     J Dent Res, 89(12): 1433-8. [Abstract] [Full-text]
115. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
     J Am Acad Dermatol, 63(6): 984-90. [Abstract] [Full-text]
116. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status.
     Metabolism, 59(12): 1794-800. [Abstract] [Full-text]
117. Premedication with dexmedetomidine alone or together with 0.5% lidocaine for IVRA.
     J Surg Res, 164(2): 242-7. [Abstract] [Full-text]
118. CT-guided sternoclavicular joint injections: description of the procedure, reliability of imaging diagnosis, and short-term patient responses.
     AJR Am J Roentgenol, 195(6): W435-9. [Abstract] [Full-text]
119. Thickened fluids for people with dementia in residential aged care facilities.
     Int J Evid Based Healthc, 8(4): 252-5. [Abstract] [Full-text]
120. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
     APMIS, 118(12): 941-8. [Abstract] [Full-text]
121. Physiological and behavioural effects of intradermal injection of sodium lauryl sulfate as an alternative to mulesing in lambs.
     Aust Vet J, 88(12): 483-9. [Abstract] [Full-text]
122. Differentiating dental pulp cells via RGD-dendrimer conjugates.
     J Dent Res, 89(12): 1433-8. [Abstract] [Full-text]
123. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
     J Am Acad Dermatol, 63(6): 984-90. [Abstract] [Full-text]
124. The impact of preoperative chemoradiotherapy on advanced low rectal cancer.
     J Surg Oncol, 102(7): 771-7. [Abstract] [Full-text]
125. Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin.
     Exp Hematol, 38(12): 1219-30. [Abstract] [Full-text]
126. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
     Prostate, 71(1): 81-90. [Abstract] [Full-text]
127. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status.
     Metabolism, 59(12): 1794-800. [Abstract] [Full-text]
128. The bacteriology of children prior to 1st stage autologous ear reconstruction.
     J Plast Reconstr Aesthet Surg, 63(12): 2001-3. [Abstract] [Full-text]
129. Premedication with dexmedetomidine alone or together with 0.5% lidocaine for IVRA.
     J Surg Res, 164(2): 242-7. [Abstract] [Full-text]
130. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
     Prostate, 71(1): 81-90. [Abstract] [Full-text]
131. Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management.
     Ann Surg, 252(6): 952-8. [Abstract] [Full-text]
132. Infusion set characteristics such as antireflux valve and dead-space volume affect drug delivery: an experimental study designed to enhance infusion sets.
     Anesth Analg, 111(6): 1427-31. [Abstract] [Full-text]
133. Augmented creatinine clearance in traumatic brain injury.
     Anesth Analg, 111(6): 1505-10. [Abstract] [Full-text]
134. Prospective assessment of short-term propylene glycol tolerance in neonates.
     Arch Dis Child, 95(12): 1054-8. [Abstract] [Full-text]
135. Prospective assessment of short-term propylene glycol tolerance in neonates.
     Arch Dis Child, 95(12): 1054-8. [Abstract] [Full-text]
136. Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients.
     J Crit Care, 25(4): 659.e1-8. [Abstract] [Full-text]
137. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases.
     Fertil Steril, 94(7): 2871-3. [Abstract] [Full-text]
138. An approach to noninvasive delivery, biodistribution, and fertility control potential evaluation of the Cuproferrogel iron oxide-copper-styrene maleic anhydride-dimethyl sulphoxide in the female.
     Fertil Steril, 94(7): 2850-3. [Abstract] [Full-text]
139. A prospective clinical study of interventional ultrasound sclerotherapy on women with hydrosalpinx before in vitro fertilization and embryo transfer.
     Fertil Steril, 94(7): 2854-6. [Abstract] [Full-text]
140. Should all oocyte donors receive prophylactic antibiotics for retrieval?
     Fertil Steril, 94(7): 2935-7. [Abstract] [Full-text]
141. Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells.
     Biomaterials, 32(4): 1041-50. [Abstract] [Full-text]
142. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
     Biomaterials, 32(4): 1242-52. [Abstract] [Full-text]
143. Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy.
     Biomaterials, 32(4): 1110-20. [Abstract] [Full-text]
144. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
     Jpn J Clin Oncol, 40(12): 1173-9. [Abstract] [Full-text]
145. Clinical analysis of thymic regrowth following chemotherapy in children and adolescents with malignant lymphoma.
     Jpn J Clin Oncol, 40(12): 1128-34. [Abstract] [Full-text]
146. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
     Jpn J Clin Oncol, 40(12): 1189-91. [Abstract] [Full-text]
147. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
     Jpn J Clin Oncol, 40(12): 1180-3. [Abstract] [Full-text]
148. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs.
     Virology, 409(1): 46-53. [Abstract] [Full-text]
149. Blocking the saphenofemoral junction during ultrasound-guided foam sclerotherapy-- assessment of a presumed safety-measure procedure.
     Eur J Vasc Endovasc Surg, 40(6): 772-6. [Abstract] [Full-text]
150. Healing and recurrence rates following ultrasound-guided foam sclerotherapy of superficial venous reflux in patients with chronic venous ulceration.
     Eur J Vasc Endovasc Surg, 40(6): 790-5. [Abstract] [Full-text]
151. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection.
     Eur J Vasc Endovasc Surg, 40(6): 817-22. [Abstract] [Full-text]
152. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
     Jpn J Clin Oncol, 40(12): 1173-9. [Abstract] [Full-text]
153. Clinical analysis of thymic regrowth following chemotherapy in children and adolescents with malignant lymphoma.
     Jpn J Clin Oncol, 40(12): 1128-34. [Abstract] [Full-text]
154. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
     Jpn J Clin Oncol, 40(12): 1189-91. [Abstract] [Full-text]
155. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
     Jpn J Clin Oncol, 40(12): 1180-3. [Abstract] [Full-text]
156. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs.
     Virology, 409(1): 46-53. [Abstract] [Full-text]
157. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.
     Int J Cancer, 128(3): 726-31. [Abstract] [Full-text]
158. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
     Int J Cancer, 128(3): 682-90. [Abstract] [Full-text]
159. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
     Int J Cancer, 128(3): 691-701. [Abstract] [Full-text]
160. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.
     Int J Cancer, 128(3): 726-31. [Abstract] [Full-text]
161. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
     Int J Cancer, 128(3): 682-90. [Abstract] [Full-text]
162. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
     Int J Cancer, 128(3): 691-701. [Abstract] [Full-text]
163. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.
     Int J Cancer, 128(3): 726-31. [Abstract] [Full-text]
164. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
     Int J Cancer, 128(3): 682-90. [Abstract] [Full-text]
165. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
     Int J Cancer, 128(3): 691-701. [Abstract] [Full-text]
166. The chemical basis of pharmacology.
     Biochemistry, 49(48): 10267-76. [Abstract] [Full-text]
167. Predictors of subarachnoid hemorrhage in acute ischemic stroke with endovascular therapy.
     Stroke, 41(12): 2775-81. [Abstract] [Full-text]
168. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA).
     Stroke, 41(12): 2840-8. [Abstract] [Full-text]
169. The chemical basis of pharmacology.
     Biochemistry, 49(48): 10267-76. [Abstract] [Full-text]
170. Predictors of subarachnoid hemorrhage in acute ischemic stroke with endovascular therapy.
     Stroke, 41(12): 2775-81. [Abstract] [Full-text]
171. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA).
     Stroke, 41(12): 2840-8. [Abstract] [Full-text]
172. Availability of experimental therapy outside oncology randomized clinical trials in the United States.
     J Clin Oncol, 28(34): 5067-73. [Abstract] [Full-text]
173. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
     J Clin Oncol, 28(34): 5110-5. [Abstract] [Full-text]
174. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.
     J Clin Oncol, 28(34): 5074-80. [Abstract] [Full-text]
175. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
     J Clin Oncol, 28(34): 5101-9. [Abstract] [Full-text]
176. Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.
     Diabetes, 59(12): 3148-58. [Abstract] [Full-text]
177. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
     J Clin Oncol, 28(34): 5097-100. [Abstract] [Full-text]
178. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.
     Cancer Lett, 300(2): 122-33. [Abstract] [Full-text]
179. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARγ ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells.
     Cancer Lett, 300(2): 134-44. [Abstract] [Full-text]
180. Bax is essential for Drp1-mediated mitochondrial fission but not for mitochondrial outer membrane permeabilization caused by photodynamic therapy.
     J Cell Physiol, 226(2): 530-41. [Abstract] [Full-text]
181. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.
     Cancer Lett, 300(2): 122-33. [Abstract] [Full-text]
182. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARγ ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells.
     Cancer Lett, 300(2): 134-44. [Abstract] [Full-text]
183. Bax is essential for Drp1-mediated mitochondrial fission but not for mitochondrial outer membrane permeabilization caused by photodynamic therapy.
     J Cell Physiol, 226(2): 530-41. [Abstract] [Full-text]
184. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.
     Cancer Lett, 300(2): 122-33. [Abstract] [Full-text]
185. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARγ ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells.
     Cancer Lett, 300(2): 134-44. [Abstract] [Full-text]
186. Bax is essential for Drp1-mediated mitochondrial fission but not for mitochondrial outer membrane permeabilization caused by photodynamic therapy.
     J Cell Physiol, 226(2): 530-41. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.